Hedge fund K2 acquires shares in Tribute Pharmaceuticals

K2 Principal Fund LP, an affiliate of Canadian hedge fund manager K2 & Associates Investment Management, has bought 9.2 million common shares and 4.7 million common share purchase warrants of Tribute Pharmaceuticals Canada Inc. Based in Milton, Ontario, Tribute is a specialty pharmaceutical company with a focus on the acquisition, licensing, development and promotion of healthcare products. As a result, K2 will own up to 14.05 percent of the company’s issued and outstanding common shares. K2 has its headquarters in Toronto.


The K2 Principal Fund L.P. Acquires Common Shares of Tribute Pharmaceuticals Canada Inc.

TORONTO, July 15, 2014 /CNW/ – The K2 Principal Fund L.P. (“K2”) announced that it has acquired 9,233,500 common shares and 4,700,000 common share purchase warrants (the “Warrants”) to purchase up to 4,700,000 common shares of Tribute Pharmaceuticals Canada Inc. (TRX) at an exercise price of $0.90 per share. The warrants expire on July 15th, 2016. As a result of the acquisition of such shares and warrants and assuming the exercise of the Warrants in full, the Partnership would own 13,933,500 common shares, representing approximately 14.05% of the issued and outstanding common shares of TRX.

K2 acquired the securities for investment purposes only and may, depending on market and other conditions, increase or decrease its beneficial ownership, control or direction over, or exercise its current rights to acquire, common shares or other securities of TRX through market transactions, private agreements or otherwise.

SOURCE K2 Principal Fund L.P.

For further information: Dan Gosselin, The K2 Principal Fund L.P., (416) 365-2155

Photo courtesy of Shutterstock